THURSDAY, SEPTEMBER 29, 2016

NewLink Genetics achieves milestone with Ebola candidate

NewLink and Merck achieve Ebola candidate milestone | Courtesy of obroncology.com

NewLink Genetics Corporation recently announced that, together with Merck, it has achieved a mutual license and collaboration deal, one that will further developments concerning the company’s Ebola vaccine candidate.

The new agreement grants NewLink Genetics $20 million as part of the crucial vaccine achievement.

"We at NewLink very much appreciate the tremendous support for these studies that we have received from our collaboration partners, including Merck, the government of Canada and the US Department of Health and Human Services (Centers for Disease Control, the National Institutes of Health and the Biomedical Advanced Research and Development Authority), the US Department of Defense and the World Health Organization, each of which has made critical contributions along the way," Dr. Charles Link, chairman, chief executive officer and chief scientific officer of NewLink Genetics, said. "We hope that the initiation of large scale clinical trials in Africa represent another step forward toward finding a solution for this difficult, global problem. This milestone payment will help us continue our significant investment into vaccines for infectious diseases, including Ebola in collaboration with Merck."

Though originally licensed by BioProtection Systems, Inc. and developed by the Public Health Agency of Canada (PHAC), the new vaccine candidate is owned entirely by NewLink Genetics Corporation. PHAC will receive a portion of the $20 million because of their part in the achievement.

Organizations in this story

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about National Institutes of Health!